Diagnostic Approach for Mast Cell Disorders

Introduction to Diagnostic Criteria

The optimal initial diagnostic approach for systemic mastocytosis (SM) combines serum tryptase measurement with bone marrow biopsy, while mast cell activation syndrome (MCAS) requires documenting acute increases in mast cell mediators during symptomatic episodes, with a serum tryptase elevation of 20% above baseline plus 2 ng/mL, measured 1-4 hours after symptom onset, as recommended by the National Comprehensive Cancer Network 1, 2, 3

For suspected systemic mastocytosis, start with peripheral blood testing using highly sensitive ASO-qPCR for KIT D816V mutation combined with baseline serum tryptase measurement, as suggested by the National Comprehensive Cancer Network 1, 2
If peripheral blood KIT D816V is positive, proceed to bone marrow biopsy and aspirate for definitive diagnosis and staging, according to the National Comprehensive Cancer Network 2, 4
Bone marrow biopsy remains the gold standard for SM diagnosis, providing detection of multifocal dense mast cell infiltrates, immunohistochemistry with CD117, CD25, and tryptase, flow cytometry for aberrant CD25 and CD2 expression on mast cells, and KIT D816V mutation analysis, as recommended by the National Comprehensive Cancer Network 4

MCAS diagnosis requires episodic symptoms affecting ≥2 organ systems concurrently, with the American Academy of Allergy, Asthma, and Immunology emphasizing that persistent daily symptoms suggest an alternative diagnosis 3
Obtain paired serum tryptase measurements, including baseline tryptase when asymptomatic and acute tryptase 1-4 hours after symptom onset, with a diagnostic threshold of 20% increase above baseline plus 2 ng/mL, as recommended by the American Academy of Allergy, Asthma, and Immunology 3, 5, 6
Add 24-hour urine mast cell mediator metabolites as complementary testing, including N-methylhistamine, 11β-prostaglandin F2α, and leukotriene E4, as suggested by the Journal of Allergy and Clinical Immunology 1, 5, 7

Timing is crucial for MCAS diagnosis, with serum tryptase drawn during the acute episode (1-4 hours after onset) and compared to a baseline value, as recommended by the Journal of Allergy and Clinical Immunology 5, 6
Bone marrow biopsy is indicated when baseline serum tryptase persistently >20 ng/mL, clinical features suggest SM, or there is a need to distinguish clonal from non-clonal mast cell disorders, as suggested by the Journal of Allergy and Clinical Immunology 1, 6, 8, 9

Initial workup for any suspected mast cell disorder includes baseline serum tryptase, peripheral blood KIT D816V by ASO-qPCR if tryptase >20 ng/mL, 24-hour urine for N-methylhistamine, 11β-PGF2α, and LTE4, and complete blood count and peripheral smear, as recommended by the National Comprehensive Cancer Network and the Journal of Allergy and Clinical Immunology 1, 2, 5
During symptomatic episodes, serum tryptase 1-4 hours after symptom onset and spot urine for mediator metabolites during symptoms should be collected, as suggested by the Journal of Allergy and Clinical Immunology and Praxis Medical Insights 3, 5, 6

Patients with typical cutaneous lesions should undergo bone‑marrow biopsy immediately, irrespective of serum tryptase level, because cutaneous disease warrants assessment for systemic involvement. 10, 11, 12

If serum tryptase is < 15 ng/mL and peripheral‑blood ASO‑qPCR for KIT D816V is negative, clinical follow‑up without bone‑marrow biopsy is appropriate unless new symptoms or signs develop. 10, 11, 12
If serum tryptase is < 15 ng/mL but peripheral‑blood ASO‑qPCR for KIT D816V is positive, a bone‑marrow biopsy should still be performed. 10, 11, 12

ASO‑qPCR on peripheral blood is the recommended initial screening technique for detecting the KIT D816V mutation in suspected systemic mastocytosis. 10, 11, 12
In adult patients with systemic mastocytosis, the KIT D816V mutation is present in at least 80 % of cases. 10, 11

In children, the KIT D816V mutation is identified in roughly 30 % of cases, whereas extracellular‑domain KIT mutations are found in about 40 % of cases. 10, 11, 13